Overview
IRON market data
Price History
IRON price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$6.01 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.90 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $40.00 – $99.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.1B · P/B 4.05.
Company News
HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $120Benzinga · Aug 6, 2026, 10:21 AM
Disc Medicine Q2 EPS $(1.54) Beats $(1.77) EstimateBenzinga · Jul 30, 2026, 12:36 PM
8-K filing — Disc Medicine, Inc. (IRON)SEC EDGAR · Jul 30, 2026, 12:32 PM
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $85Benzinga · Jun 16, 2026, 1:35 PM
Disc Medicine Completes FDA Type A Meeting Regarding The Complete Response Letter To The New Drug Application For Bitopertin In Erythropoietic Protoporphyria; Data From APOLLO Phase 3 Study Expected In Q4 2026Benzinga · Jun 9, 2026, 12:40 PM
Disc Medicine Presents Updated Data From Myelofibrosis And Anemia Treatment RALLY-MF Phase 2 Trial Showing Reductions In Hepcidin And Higher Iron Levels, A Positive Clinical Impact On Anemia Measures Across A Broad Range Of Patient TypesBenzinga · Jun 2, 2026, 12:07 PM
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $80Benzinga · May 14, 2026, 5:00 PM